BW
VEGFR2 polyclonal Antibody | BS91436
- SKU:
- BW-BS91436
- Availability:
- Usually ships in 5 working days
Description
VEGFR2 polyclonal Antibody | BS91436 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Application: WB ICC IHC IP
Application Range: WB:1:500-1:1,000 ICC:1:50-1:200 IHC:1:50-1:100
Background: Three cell membrane receptor tyrosine kinases, Flt (also designated VEGF-R1) (1-3), Flk-1 (also designated VEGF-R2) (4-6) and Flt-4, putatively involved in the growth of endothelial cells, are characterized by the presence of seven immunoglobulin-like sequences in their extracellular domain. These receptors exhibit high degrees of sequence relatedness to each other as well as lesser degrees of relatedness to the class III receptors including CSF-1/Fms, PDGR, SLFR/Kit and Flt-3/Flk-2. Two members of this receptor class, Flt-1 and Flk-1, have been shown to represent high affinity receptors for vascular endothelial growth factors (VEGFs) (3,5) . On the basis of structural similarity to Flt and Flk-1, it has been speculated that Flt-4 might represent a third receptor for either VEGF or a VEGF-related ligand.
Storage & Stability: Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Specificity: VEGFR2 polyclonal Antibody detects endogenous levels of VEGFR2 protein.
Molecular Weight: 152 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: VEGFR-2, FLK-1, KDR, CD309, CD309 antigen, EC 2.7.10.1, Fetal liver kinase 1, FLK-1, FLK1, FLK1, mouse, homolog of, Kdr, Kinase insert domain receptor (a type III receptor tyrosine kinase), Kinase insert domain receptor, KRD1, Ly73, Protein tyrosine kinase receptor FLK1, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, Tyrosine kinase growth factor receptor, Vascular endothelial growth factor receptor 2, VEGFR 2, VEGFR, VEGFR-2, VEGFR2, VGFR2,
Immunogen: recombinant protein
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: ProA affinity purified
Pathway: